Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals
Sub-Industry: Pharmaceuticals
Symbol: NYSE:LLY
CUSIP: 53245710
Web: www.lilly.com

Capitalization:

Market Cap: $92.38399 billion
Outstanding Shares: 1,055,000,000

Average Prices:

50 Day Moving Avg: $80.84
200 Day Moving Avg: $82.02
52 Week Range: $64.18 - $86.72

P/E:

Trailing P/E Ratio: 36.31
Foreward P/E Ratio: 18.36
P/E Growth: 1.76

Sales & Book Value:

Annual Revenue: $22 billion
Price / Sales: 4.02
Book Value: $13.37 per share
Price / Book: 6.28

Dividend:

Annual Dividend: $2.08
Dividend Yield: 2.5%

Profitability:

EBIDTA: $5.99 billion
Net Margins: 11.12%
Return on Equity: 28.71%
Return on Assets: 10.74%

Debt:

Debt-to-Equity Ratio: 0.70%
Current Ratio: 1.39%
Quick Ratio: 1.01%

Misc:

Average Volume: 3.48 million shs.
Beta: 0.34
Short Ratio: 2.62

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Tuesday, July, 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. The business earned $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and Company had a net margin of 11.12% and a return on equity of 28.71%. The company's revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

18 analysts have issued 1 year price targets for Eli Lilly and Company's stock. Their predictions range from $71.00 to $105.00. On average, they expect Eli Lilly and Company's share price to reach $89.18 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Some companies that are related to Eli Lilly and Company include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO) and Akorn (AKRX).

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

David A. Ricks, Chairman of the Board, President, Chief Executive Officer
Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Michael J. Harrington, Senior Vice President, General Counsel
Stephen F. Fry, Senior Vice President - Human Resources and Diversity
Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.76%), Vanguard Group Inc. (6.65%), BlackRock Inc. (6.03%), State Street Corp (3.98%), Franklin Resources Inc. (2.66%) and State Farm Mutual Automobile Insurance Co. (1.89%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Winslow Capital Management LLC, Franklin Resources Inc., Bank of New York Mellon Corp, FMR LLC, American Century Companies Inc., UBS Asset Management Americas Inc. and Capital Guardian Trust Co.. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dodge & Cox, Renaissance Technologies LLC, Harbour Capital Advisors LLC, Vanguard Group Inc., AJO LP, Westfield Capital Management Co. LP and BlackRock Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $83.91.

MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		693 (Vote Outperform)
Underperform Votes:		515 (Vote Underperform)
Total Votes:		1,208

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:	Buy (Score: 2.56)
Consensus Price Target:	$89.18 (6.28% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/15/2017	Morgan Stanley	Reiterated Rating	Hold	$86.00	Low
9/11/2017	Jefferies Group LLC	Reiterated Rating	Buy	$89.00 -> $89.00	Low
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$103.00 -> $105.00	Low
9/6/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00 -> $71.00	Low
8/31/2017	Leerink Swann	Reiterated Rating	Hold		Low
8/4/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	Low
7/26/2017	Oppenheimer Holdings, Inc.	Downgrade	Outperform -> Market Perform	$90.00 -> $90.00	Low
7/17/2017	Deutsche Bank AG	Reiterated Rating	Buy	$90.00 -> $91.00	Low
7/4/2017	Citigroup Inc.	Reiterated Rating	Buy	$100.00	Low
7/4/2017	Barclays PLC	Boost Price Target	Overweight	$85.00 -> $90.00	Low
5/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform	$88.00	Medium
5/16/2017	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Conviction-Buy -> Buy	$92.00	High
4/27/2017	Argus	Downgrade	Buy -> Hold	$64.18 -> $81.00	Low
4/19/2017	Credit Suisse Group	Reiterated Rating	Outperform	$87.00	Low
4/17/2017	Cowen and Company	Boost Price Target	Outperform	$85.00 -> $95.00	Medium
11/26/2016	J P Morgan Chase & Co	Reiterated Rating	Overweight		N/A
11/25/2016	Atlantic Securities	Downgrade	Overweight -> Neutral		N/A
10/27/2016	Societe Generale	Reiterated Rating	Hold	$78.00	N/A
6/15/2016	SunTrust Banks, Inc.	Reiterated Rating	Buy		N/A
12/22/2015	Bank of America Corporation	Reiterated Rating	Buy	$104.00 -> $108.00	N/A

(Data available from 9/26/2015 forward)

Earnings History for Eli Lilly and Company (NYSE:LLY)

Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)

Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/24/2017		$1.03					N/A
7/25/2017	Q2 2017	$1.05	$1.11	$5.60 billion	$5.82 billion	View	N/A
4/25/2017	Q1 17	$0.96	$0.98	$5.22 billion	$5.23 billion	View	N/A
1/31/2017	Q416	$0.98	$0.95	$5.54 billion	$5.76 billion	View	N/A
10/25/2016	Q316	$0.96	$0.88	$4.23 billion	$5.19 billion	View	Listen
7/26/2016	Q216	$0.86	$0.86	$5.14 billion	$5.40 billion	View	Listen
4/26/2016	Q116	$0.85	$0.83	$4.82 billion	$4.87 billion	View	Listen
1/28/2016	Q415	$0.78	$0.78	$5.33 billion	$5.38 billion	View	Listen
10/22/2015	Q315	$0.76	$0.89	$4.99 billion	$4.96 billion	View	Listen
7/23/2015	Q215	$0.74	$0.90	$4.89 billion	$4.98 billion	View	Listen
4/23/2015	Q115	$0.76	$0.87	$4.62 billion	$4.64 billion	View	N/A
1/30/2015	Q414	$0.74	$0.75	$5.21 billion	$5.12 billion	View	N/A
10/23/2014	Q314	$0.66	$0.66	$4.83 billion	$4.88 billion	View	Listen
7/24/2014	Q214	$0.66	$0.68	$4.88 billion	$4.94 billion	View	N/A
4/24/2014	Q114	$0.70	$0.70	$4.78 billion	$4.68 billion	View	N/A
1/30/2014	Q413	$0.72	$0.74	$5.46 billion	$5.81 billion	View	Listen
10/23/2013	Q313	$1.04	$1.11	$5.76 billion	$5.77 billion	View	N/A
7/24/2013	Q2 2013	$1.01	$1.16	$5.82 billion	$5.93 billion	View	N/A
4/24/2013	Q1 2013	$1.05	$1.14	$5.66 billion	$5.60 billion	View	N/A
1/29/2013	Q4 2012	$0.82	$0.85	$5.78 billion	$5.96 billion	View	N/A
10/24/2012		$0.82	$0.79			View	N/A
7/25/2012		$0.76	$0.83			View	N/A
4/25/2012		$0.80	$0.92			View	N/A
1/31/2012		$0.80	$0.87			View	N/A
10/20/2011		$1.12	$1.13			View	N/A
7/21/2011		$1.18	$1.18			View	N/A
4/18/2011		$1.16	$1.24			View	N/A
1/27/2011		$1.10	$1.11			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)

2017 EPS Consensus Estimate: $4.10

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	$0.98	$0.98	$0.98
Q2 2017	2	$1.04	$1.06	$1.05
Q3 2017	2	$1.03	$1.06	$1.05
Q4 2017	2	$1.01	$1.04	$1.03

(Data provided by Zacks Investment Research)

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)

Most Recent Dividend:	9/8/2017
Annual Dividend:	$2.08
Dividend Yield:	2.48%
Dividend Growth:	1.30% (3 Year Average)
Payout Ratio:	90.04% (Trailing 12 Months of Earnings) 50.12% (Based on This Year's Estimates) 45.51% (Based on Next Year's Estimates)
Track Record:	2 Years of Consecutive Dividend Growth

Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2017	quarterly	$0.52	2.51%	8/11/2017	8/15/2017	9/8/2017
5/1/2017	quarterly	$0.52	2.55%	5/11/2017	5/15/2017	6/9/2017
12/13/2016	quarterly	$0.52	3.03%	2/13/2017	2/15/2017	3/10/2017
10/17/2016	quarterly	$0.51	2.59%	11/10/2016	11/15/2016	12/9/2016
6/20/2016	quarterly	$0.51	2.81%	8/11/2016	8/15/2016	9/9/2016
5/2/2016	quarterly	$0.51	2.68%	5/11/2016	5/13/2016	6/10/2016
12/8/2015	quarterly	$0.51	2.43%	2/10/2016	2/12/2016	3/10/2016
10/19/2015	quarterly	$0.50	2.57%	11/10/2015	11/13/2015	12/10/2015
6/15/2015	quarterly	$0.50	2.42%	8/12/2015	8/14/2015	9/10/2015
5/4/2015	quarterly	$0.50	2.78%	5/14/2015	5/18/2015	6/10/2015
12/15/2014	quarterly	$0.50	2.89%	2/11/2015	2/13/2015	3/10/2015
10/20/2014	quarterly	$0.49	3.03%	11/12/2014	11/14/2014	12/10/2014
6/16/2014	quarterly	$0.49	3.31%	8/13/2014	8/15/2014	9/10/2014
5/5/2014	quarterly	$0.49	3.35%	5/13/2014	5/15/2014	6/10/2014
12/16/2013	quarterly	$0.49	3.98%	2/12/2014	2/14/2014	3/10/2014
10/21/2013	quarterly	$0.49	3.91%	11/13/2013	11/15/2013	12/10/2013
6/18/2013	quarterly	$0.49	3.82%	8/13/2013	8/15/2013	9/10/2013
5/6/2013	quarterly	$0.49	3.62%	5/14/2013	5/16/2013	6/10/2013
12/17/2012	quarterly	$0.49	3.96%	2/13/2013	2/15/2013	3/8/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)

Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.72%

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2017	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$82.53	$15,680,700.00
8/31/2017	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$81.06	$14,590,800.00
7/31/2017	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$83.09	$18,279,800.00
6/22/2017	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$84.43	$17,730,300.00
6/20/2017	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$83.05	$17,855,750.00
6/12/2017	Melissa S Barnes	Insider	Sell	1,900	$80.78	$153,482.00
6/9/2017	Michael J Harrington	VP	Sell	22,833	$79.97	$1,825,955.01
5/4/2017	Enrique A Conterno	SVP	Sell	25,000	$82.76	$2,069,000.00
3/30/2017	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$84.67	$17,780,700.00
2/17/2017	Lilly Endowment Inc	Major Shareholder	Sell	230,000	$80.27	$18,462,100.00
2/6/2017	Alfonso G Zulueta	SVP	Sell	15,000	$77.66	$1,164,900.00
2/3/2017	Derica W Rice	EVP	Sell	11,162	$77.14	$861,036.68
2/2/2017	Donald A Zakrowski	Insider	Sell	2,000	$77.52	$155,040.00
2/1/2017	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$77.35	$17,017,000.00
12/16/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$72.59	$14,518,000.00
12/16/2016	Melissa S Barnes	Insider	Sell	2,093	$82.23	$172,107.39
12/16/2016	R David Hoover	Director	Buy	500	$71.85	$35,925.00
12/16/2016	Susan Mahony	SVP	Sell	20,242	$72.65	$1,470,581.30
10/5/2016	Maria A Crowe	Insider	Sell	2,248	$81.37	$182,919.76
8/15/2016	Jackson P Tai	Director	Buy	5,773	$80.43	$464,322.39
8/12/2016	Jackson P Tai	Director	Buy	2,560	$80.42	$205,875.20
7/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	205,000	$82.94	$17,002,700.00
7/28/2016	Donald A Zakrowski	Insider	Sell	1,213	$83.16	$100,873.08
7/28/2016	Lilly Endowment Inc	Major Shareholder	Sell	240,000	$82.87	$19,888,800.00
7/12/2016	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$79.54	$16,703,400.00
7/7/2016	Lilly Endowment Inc	Major Shareholder	Sell	225,000	$79.14	$17,806,500.00
6/30/2016	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$78.46	$16,868,900.00
6/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	220,000	$77.86	$17,129,200.00
6/10/2016	Melissa S Barnes	SVP	Sell	992	$73.77	$73,179.84
5/31/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$75.12	$15,024,000.00
5/12/2016	Jackson P Tai	Director	Buy	1,080	$75.75	$81,810.00
5/12/2016	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$75.86	$14,413,400.00
5/2/2016	Donald A Zakrowski	CAO	Sell	1,600	$75.86	$121,376.00
4/29/2016	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$75.44	$13,579,200.00
4/27/2016	Alfonso G Zulueta	SVP	Sell	12,000	$76.27	$915,240.00
4/8/2016	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$74.29	$14,858,000.00
2/5/2016	Stephen F Fry	SVP	Sell	15,230	$78.87	$1,201,190.10
2/3/2016	David A. Ricks	SVP	Sell	5,733	$77.66	$445,224.78
2/3/2016	Derica W. Rice	CFO	Sell	10,483	$77.78	$815,367.74
2/1/2016	Jackson P Tai	Director	Buy	3,170	$78.62	$249,225.40
1/29/2016	Alfonso G Zulueta	SVP	Sell	5,000	$78.75	$393,750.00
12/21/2015	Lilly Endowment Inc	Major Shareholder	Sell	205,000	$86.00	$17,630,000.00
12/15/2015	Lilly Endowment Inc	Major Shareholder	Sell	215,000	$85.60	$18,404,000.00
12/9/2015	Enrique A Conterno	VP	Sell	25,000	$83.88	$2,097,000.00
12/2/2015	Lilly Endowment Inc	major shareholder	Sell	210,000	$85.09	$17,868,900.00
11/20/2015	Lilly Endowment Inc	major shareholder	Sell	205,000	$84.54	$17,330,700.00
10/29/2015	Lilly Endowment Inc	major shareholder	Sell	200,000	$82.28	$16,456,000.00
10/9/2015	Lilly Endowment Inc	major shareholder	Sell	215,000	$85.86	$18,459,900.00
10/5/2015	Lilly Endowment Inc	major shareholder	Sell	260,000	$86.46	$22,479,600.00
9/18/2015	Lilly Endowment Inc	major shareholder	Sell	250,000	$89.04	$22,260,000.00
6/10/2015	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$82.39	$17,301,900.00
6/4/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$77.90	$15,580,000.00
5/29/2015	Jeffrey N Simmons	SVP	Sell	20,000	$78.08	$1,561,600.00
5/20/2015	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$73.43	$13,951,700.00
5/15/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$72.83	$14,566,000.00
5/8/2015	Lilly Endowment Inc	Major Shareholder	Sell	195,000	$73.28	$14,289,600.00
5/1/2015	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$73.09	$14,618,000.00
3/30/2015	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$73.94	$13,309,200.00
3/23/2015	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$76.97	$14,624,300.00
3/9/2015	Stephen F Fry	SVP	Sell	4,000	$69.27	$277,080.00
2/4/2015	David A Ricks	SVP	Sell	3,147	$69.99	$220,258.53
2/4/2015	Derica W Rice	CFO	Sell	5,316	$70.00	$372,120.00
2/4/2015	Jan M Lundberg	EVP	Sell	11,085	$70.08	$776,836.80
2/3/2015	Jan M Lundberg	EVP	Sell	121,711	$70.78	$8,614,704.58
2/2/2015	David A Ricks	SVP	Sell	4,769	$71.51	$341,031.19
2/2/2015	Derica W Rice	CFO	Sell	10,068	$71.84	$723,285.12
12/4/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$71.92	$13,664,800.00
12/2/2014	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$70.14	$12,625,200.00
11/13/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$67.73	$13,546,000.00
11/5/2014	Lilly Endowment Inc	Major Shareholder	Sell	180,000	$67.00	$12,060,000.00
11/4/2014	Fionnuala M Walsh	SVP	Sell	15,000	$67.00	$1,005,000.00
11/3/2014	Enrique A Conterno	VP	Sell	5,000	$66.03	$330,150.00
10/31/2014	Fionnuala M Walsh	SVP	Sell	7,376	$66.58	$491,094.08
10/31/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$66.40	$12,616,000.00
10/30/2014	Lilly Endowment Inc	Major Shareholder	Sell	175,000	$66.58	$11,651,500.00
10/24/2014	Maria A Crowe	Insider	Sell	2,750	$65.77	$180,867.50
10/6/2014	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$65.63	$13,782,300.00
10/1/2014	Enrique A Conterno	VP	Sell	5,000	$64.86	$324,300.00
9/30/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$65.07	$13,014,000.00
9/10/2014	Lilly Endowment Inc	Major Shareholder	Sell	210,000	$64.77	$13,601,700.00
9/3/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$63.99	$12,798,000.00
9/2/2014	Enrique A Conterno	VP	Sell	5,000	$63.60	$318,000.00
7/29/2014	Lilly Endowment Inc	Major Shareholder	Sell	250,000	$63.03	$15,757,500.00
7/28/2014	Susan Mahony	SVP	Sell	2,065	$63.30	$130,714.50
7/25/2014	Enrique A Conterno	VP	Sell	10,000	$63.79	$637,900.00
7/25/2014	Susan Mahony	SVP	Sell	30,000	$63.90	$1,917,000.00
7/1/2014	Lilly Endowment Inc	Major Shareholder	Sell	235,000	$62.30	$14,640,500.00
6/25/2014	Lilly Endowment Inc	Major Shareholder	Sell	245,000	$62.68	$15,356,600.00
6/20/2014	Lilly Endowment Inc	Major Shareholder	Sell	230,000	$61.55	$14,156,500.00
6/16/2014	Lilly Endowment Inc	Major Shareholder	Sell	200,000	$58.73	$11,746,000.00
6/5/2014	Lilly Endowment Inc	Major Shareholder	Sell	190,000	$59.53	$11,310,700.00
5/21/2014	Lilly Endowment Inc	major shareholder	Sell	230,000	$58.90	$13,547,000.00
5/12/2014	Jackson Tai	Director	Buy	17,157	$59.19	$1,015,522.83
5/12/2014	Lilly Endowment Inc	major shareholder	Sell	210,000	$59.33	$12,459,300.00
5/6/2014	Lilly Endowment Inc	major shareholder	Sell	190,000	$58.79	$11,170,100.00
4/29/2014	Lilly Endowment Inc	major shareholder	Sell	200,000	$59.43	$11,886,000.00
4/28/2014	Lilly Endowment Inc	major shareholder	Sell	150,000	$58.64	$8,796,000.00
8/15/2013	Enrique Conterno	VP	Sell	5,000	$53.79	$268,950.00
7/29/2013	Jacques Tapiero	SVP	Sell	7,500	$53.74	$403,050.00
7/15/2013	Enrique A Conterno	VP	Sell	5,000	$51.43	$257,150.00
6/17/2013	Enrique A Conterno	VP	Sell	5,000	$52.45	$262,250.00
5/15/2013	Enrique A Conterno	VP	Sell	5,000	$56.15	$280,750.00
5/10/2013	Jeffrey N Simmons	SVP	Sell	10,000	$54.49	$544,900.00
3/26/2013	Susan Mahony	SVP	Sell	5,000	$56.00	$280,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Eli Lilly and Company (NYSE:LLY) Latest Headlines for Eli Lilly and Company (NYSE:LLY)

Source:

Date	Headline
	Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for ... - PR Newswire (press release) www.prnewswire.com - September 25 at 7:04 PM
	Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death finance.yahoo.com - September 25 at 8:33 AM
	Colorectal Cancer Market: Global Industry Analysis Trends, Share, Growth Drivers, Outlook and 2025 Forecasts Research Report finance.yahoo.com - September 22 at 11:51 AM
	Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune Pharma, Eli Lilly, and Merck www.prnewswire.com - September 22 at 11:51 AM
	Global Animal Health Market: Industry Analysis & Outlook 2017-2021 - Research and Markets www.businesswire.com - September 21 at 3:49 PM
	Recombinant DNA Technology Market Analysis By Product, By Component, By Application, By End-use And Segment Forecasts, 2014 - 2025 www.prnewswire.com - September 21 at 3:49 PM
	Eli Lilly and Company (LLY) Major Shareholder Sells $15,680,700.00 in Stock www.americanbankingnews.com - September 18 at 4:16 PM
	FY2017 EPS Estimates for Eli Lilly and Company Raised by Analyst (LLY) www.americanbankingnews.com - September 18 at 2:56 AM
	Lilly/Incyte pill beats placebo in mid-stage eczema trial - Reuters - Reuters www.reuters.com - September 17 at 12:44 AM
	Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study finance.yahoo.com - September 16 at 6:04 AM
	Eli Lilly Still Looking for Lower Prices finance.yahoo.com - September 16 at 6:04 AM
	Eli Lilly and Company (LLY) Rating Reiterated by Morgan Stanley www.americanbankingnews.com - September 15 at 5:32 PM
	Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Announces Baricitinib Meets Primary Endpoint in Phase 2 Study www.streetinsider.com - September 15 at 6:06 AM
	Eli Lilly Partnering Deals and Alliances 2010 to 2017 finance.yahoo.com - September 15 at 6:06 AM
	Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017 finance.yahoo.com - September 15 at 6:06 AM
	Eli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.50 Billion www.americanbankingnews.com - September 15 at 5:20 AM
	Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control finance.yahoo.com - September 14 at 7:16 AM
	Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 12, 2017 finance.yahoo.com - September 14 at 7:16 AM
	Is Lilly Headed for the Valley? finance.yahoo.com - September 14 at 7:16 AM
	Zacks: Analysts Anticipate Eli Lilly and Company (LLY) to Announce $1.03 EPS www.americanbankingnews.com - September 14 at 12:24 AM
	Lilly Cuts Back Again - Seeking Alpha seekingalpha.com - September 13 at 5:53 AM
	Eli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study www.streetinsider.com - September 12 at 3:41 AM
	Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress finance.yahoo.com - September 12 at 3:41 AM
	Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : September 11, 2017 finance.yahoo.com - September 12 at 3:41 AM
	Eli Lilly & Co. (LLY) Presents Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data ... - StreetInsider.com www.streetinsider.com - September 11 at 10:38 PM
	Eli Lilly & Co. (LLY) to Present New Data for Olumiant and Taltz at EADV - StreetInsider.com www.streetinsider.com - September 11 at 10:38 PM
	Eli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study - StreetInsider.com www.streetinsider.com - September 11 at 10:38 PM
	Eli Lilly and Company (LLY) Earns Buy Rating from Jefferies Group LLC www.americanbankingnews.com - September 11 at 5:46 PM
	Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer finance.yahoo.com - September 10 at 6:00 AM
	Lilly Breast Cancer Drug Results May Challenge Pfizer Pill finance.yahoo.com - September 10 at 12:57 AM
	Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs www.wsj.com - September 9 at 7:55 PM
	IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine finance.yahoo.com - September 9 at 7:55 PM
	Eli Lilly and Company (LLY) Earns "Overweight" Rating from Piper Jaffray Companies www.americanbankingnews.com - September 9 at 11:58 AM
	Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study www.rttnews.com - September 9 at 5:18 AM
	Eli Lilly To Cut 8 Percent Of Jobs www.msn.com - September 9 at 5:18 AM
	Eli Lilly Hopes to Benefit From Joining the Layoff Brigade — 3,500 Pink Slips! 247wallst.com - September 9 at 5:18 AM
	Drugmaker Eli Lilly Will Cut 3,500 Jobs www.bloomberg.com - September 9 at 5:18 AM
	Hurricane Irma Bears Down on Equities and Disney Slide Hits Dow finance.yahoo.com - September 9 at 5:17 AM
	IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine finance.yahoo.com - September 9 at 5:17 AM
	Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective finance.yahoo.com - September 9 at 5:17 AM
	Understanding Merck’s Valuation after 2Q17 finance.yahoo.com - September 9 at 5:17 AM
	Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018 finance.yahoo.com - September 9 at 5:17 AM
	Drugmaker Lilly to trim workforce by nearly 9 percent abcnews.go.com - September 8 at 6:23 AM
	SunTrust Banks Equities Analysts Raise Earnings Estimates for Eli Lilly and Company (LLY) www.americanbankingnews.com - September 8 at 6:00 AM
	Lilly to cut 8 percent of jobs in bid to cut costs - Reuters www.reuters.com - September 8 at 1:33 AM
	Eli Lilly: 3,500 job cuts to make firm stronger, CEO says - USA Today - USA TODAY www.usatoday.com - September 8 at 1:33 AM
	PRESS DIGEST - Wall Street Journal - Sept 8 finance.yahoo.com - September 8 at 1:33 AM
	[$$] Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs finance.yahoo.com - September 8 at 1:33 AM
	Analyzing GlaxoSmithKline PLC (GSK) and Eli Lilly and (LLY) www.americanbankingnews.com - September 7 at 12:50 PM
	Eli Lilly and Co (LLY) Layoffs: Drugmaker to Cut 3,500 Jobs investorplace.com - September 7 at 12:29 PM